RxDoctor Payments Data

David Zhao, MD

Interventional Cardiology · Winston Salem, NCNPI 1366411159

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (54.2%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 60.1% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $30,359 and has fallen 89.0% since, to $3,346 in 2025. Among interventional cardiology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$77,541in general payments, 2019–2025

Across 153 payments — averaging $506.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$47K
  • Medtronic$15K
  • Edwards Lifesciences$9K
  • Angiodynamics, Inc.$3K
  • Abbott$3K
  • Longeviti Neuro Solutions Inc$209
  • plus $530 from 5 others
$684,068in research payments, 2019–2025

Across 114 payments — averaging $6000.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$552K
  • Medtronic$132K

What the payments were for

  • Consulting fees$42,02554%
  • Speaking & faculty fees$15,80020%
  • Travel & lodging$12,76816%
  • Food & beverage$6,9489%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,541 in reported general payments places this provider in the 90th percentile of 180 interventional cardiology providers in North Carolina.

See all interventional cardiology providers in North Carolina

Medicare billing

Part B allowed, 2024
$94,056
Medicare patients
285
Services billed
469

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban56$52,486
Atorvastatin Calcium52$640
ClopidogrelClopidogrel Bisulfate37$405
Carvedilol51$392
Ezetimibe19$381
Metoprolol Succinate47$318
Isosorbide Mononitrate ErIsosorbide Mononitrate23$292
Furosemide52$270
Rosuvastatin Calcium15$238
Amlodipine Besylate23$237
Pantoprazole Sodium12$195
Losartan Potassium24$139
Lisinopril21$126
Metoprolol Tartrate40$122
Spironolactone14$80

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Winston Salem

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →